Daniel L Karl Selected Research

Daniel L Karl Research Topics

6	Neoplasms (Cancer) 10/2021 - 11/2010
3	Sarcoma (Soft Tissue Sarcoma) 01/2015 - 11/2011
2	Leukemia 01/2018 - 01/2017
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018 - 01/2017
1	Breast Neoplasms (Breast Cancer) 01/2020
1	Lymphoma (Lymphomas) 01/2018
1	Necrosis 01/2013
1	Hypoxia (Hypoxemia) 01/2013
1	Hypertension (High Blood Pressure) 11/2011
1	Hepatocellular Carcinoma (Hepatoma) 07/2011
1	Hepatitis C 07/2011
1	Fibrosis (Cirrhosis) 07/2011
1	Neoplasm Micrometastasis 11/2010
1	Carcinoma (Carcinomatosis) 11/2010
1	Renal Cell Carcinoma (Grawitz Tumor) 11/2010
1	Neoplasm Metastasis (Metastasis) 11/2010

3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2015 - 11/2010
3	Bevacizumab (Avastin)FDA Link 01/2015 - 11/2011
2	Pharmaceutical PreparationsIBA 01/2015 - 01/2013
2	Biomarkers (Surrogate Marker)IBA 01/2015 - 11/2011
1	AcetyltransferasesIBA 10/2021
1	Estrogen ReceptorsIBA 01/2020
1	Phenobarbital (Luminal)FDA Link 01/2020
1	Estrogens (Estrogen)FDA Link 01/2020
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2018
1	Protein-Arginine N-Methyltransferases (Methyltransferase, Protein Arginine)IBA 01/2018
1	Histones (Histone)IBA 01/2018
1	Lysine AcetyltransferasesIBA 01/2018
1	Caspase 3 (Caspase-3)IBA 01/2017
1	Oncogene Proteins (Oncogene Protein)IBA 01/2017
1	Tumor Biomarkers (Tumor Markers)IBA 01/2015
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2015
1	Carbonic Anhydrase IXIBA 01/2013
1	Small Interfering RNA (siRNA)IBA 01/2013
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2013
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2013
1	DNA (Deoxyribonucleic Acid)IBA 01/2013
1	Antiviral Agents (Antivirals)IBA 07/2011
1	Epidermal Growth Factor (EGF)IBA 07/2011
1	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 11/2010
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 11/2010